Cardiovascular

Fuatilia
Illustration of hemodialysis patient with fish oil supplements and PISCES trial graph showing 43% reduction in cardiovascular events.
Picha iliyoundwa na AI

High-dose fish oil linked to 43% fewer serious cardiovascular events in hemodialysis patients, trial reports

Imeripotiwa na AI Picha iliyoundwa na AI Imethibitishwa ukweli

A large international randomized trial found that 4 grams a day of omega-3 fish oil was associated with a 43% lower rate of serious cardiovascular events among adults receiving maintenance hemodialysis. The PISCES study enrolled 1,228 participants at 26 sites in Australia and Canada; results were presented at the American Society of Nephrology’s Kidney Week 2025 and published in The New England Journal of Medicine.

Brazil's Anvisa approved on Monday, February 2, 2026, the expansion of therapeutic indications for semaglutide, the active ingredient in Wegovy and Ozempic. Wegovy can now be used to reduce the risk of heart attacks and strokes in adults with cardiovascular disease and overweight, while Ozempic is indicated for type 2 diabetes associated with chronic kidney disease. The agency is also reviewing a request for an oral version of Wegovy.

Imeripotiwa na AI Imethibitishwa ukweli

A comprehensive review in Beverage Plant Research concludes that evidence from human studies most strongly supports an association between tea consumption—particularly green tea—and lower risks of cardiovascular disease, obesity, type 2 diabetes and some cancers, while calling evidence for brain and muscle benefits “promising” but less settled. The authors also caution that bottled and bubble tea products, which can include added sugar and other additives, may blunt tea’s potential advantages.

Researchers at the University of Barcelona have discovered that combining two existing medications, pemafibrate and telmisartan, significantly reduces liver fat in animal models of metabolic dysfunction-associated steatotic liver disease (MASLD). This approach could offer a safer treatment option for the condition, which affects about one in three adults worldwide. The findings highlight the potential of drug repurposing to address a disease with limited current therapies.

Alhamisi, 15. Mwezi wa kwanza 2026, 18:18:23

Statins reduce risks for type 2 diabetes patients at all heart levels

Jumamosi, 22. Mwezi wa kumi na moja 2025, 03:03:02

Light smoking raises heart disease risk for decades

Jumatatu, 3. Mwezi wa kumi na moja 2025, 14:14:29

Study links nighttime artificial light to higher cardiovascular risk

Jumatatu, 3. Mwezi wa kumi na moja 2025, 01:22:17

Longevity-linked BPIFB4 variant improves heart function in progeria models

Alhamisi, 23. Mwezi wa kumi 2025, 13:56:53

New DNA-based therapy reduces cholesterol by nearly 50 percent

Tovuti hii inatumia vidakuzi

Tunatumia vidakuzi kwa uchambuzi ili kuboresha tovuti yetu. Soma sera ya faragha yetu kwa maelezo zaidi.
Kataa